Genzada Pharmaceuticals has awarded Dr. Kwatra, Director of Glioblastoma Drug Discovery Group at Duke, a two-year, $763,200 grant, titled “Evaluation of novel anti-cancer agents, either alone or in combination, for activity against glioblastoma subtypes: a personalized medicine approach.”
Genzada specializes in pharmaceuticals derived from plants. Their lead compounds have shown activity in preclinical models of several cancers and can penetrate the blood brain barrier. Thus, this could potentially give rise to a natural, alternative therapy against GBM. The compounds will be tested against a diverse molecular profile of GBMs, allowing for a personalized and targeted approach.
Read more here: https://anesthesiology.duke.edu/?p=840707
Leave a Reply